A retrospective study to explore the biomarkers in lung cancer immunotherapy, 2nd stage -irAE prediction-

A retrospective study to explore the biomarkers in lung cancer immunotherapy, 2nd stage -irAE prediction- - Immuno-Oncology Biomarker Study-II_irAE (LC-SCRUM-IBIS-II_irAE)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000051528

Enrollment

350

Registered

2023-07-06

Start date

2023-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients whose whole exome sequence data have been collected in the LC-SCRUM-IBIS study. 2) Patients who consented to the secondary use of the genetic analysis data and clinical information.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
HLA alleles	—

Countries

Japan

Contacts

Public ContactKaname Nosaki

National Cancer Center Hospital East Department of Thoracic Oncology

knosaki@east.ncc.go.jp04-7133-1111

Outcome results